Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

83 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
"Real-world" evaluation of 18F-Choline PET/CT practices in prostate cancer patients and impact on changes in therapeutic strategy.
Niziers V, Boissier R, Borchiellini D, Deville JL, Khoury C, Durand M, Toledano H, Albert T, Branger N, Bandelier Q, Ouvrier MJ, Gabriel S, Hoch B, Gross E, Walz J, Brenot-Rossi I, Pignot G. Niziers V, et al. Among authors: borchiellini d. Urol Oncol. 2020 Jan;38(1):2.e1-2.e9. doi: 10.1016/j.urolonc.2019.07.017. Epub 2019 Aug 22. Urol Oncol. 2020. PMID: 31447087
Loco-regional treatment for castration-resistant prostate cancer: Is there any rationale? A critical review from the AFU-GETUG.
Beauval JB, Loriot Y, Hennequin C, Rozet F, Barthelemy P, Borchiellini D, Schlürmann Constans F, Gross E, Maillet D, Pasticier G, Pignot G, Timsit MO, Vincendeau S, Ploussard G, Sargos P. Beauval JB, et al. Among authors: borchiellini d. Crit Rev Oncol Hematol. 2018 Feb;122:144-149. doi: 10.1016/j.critrevonc.2017.12.012. Epub 2017 Dec 30. Crit Rev Oncol Hematol. 2018. PMID: 29458782 Review.
Systemic treatments for high-risk localized prostate cancer.
Pignot G, Maillet D, Gross E, Barthelemy P, Beauval JB, Constans-Schlurmann F, Loriot Y, Ploussard G, Sargos P, Timsit MO, Vincendeau S, Pasticier G, Borchiellini D. Pignot G, et al. Among authors: borchiellini d. Nat Rev Urol. 2018 Aug;15(8):498-510. doi: 10.1038/s41585-018-0017-x. Nat Rev Urol. 2018. PMID: 29765147 Review.
Management of non-metastatic castrate-resistant prostate cancer: A systematic review.
Loriot Y, Supiot S, Beauval JB, Schlürmann F, Pasticier G, Sargos P, Barthélémy P, Pignot G, Maillet D, Vincendeau S, Gross E, Ploussard G, Timsit MO, Borchiellini D. Loriot Y, et al. Among authors: borchiellini d. Cancer Treat Rev. 2018 Nov;70:223-231. doi: 10.1016/j.ctrv.2018.09.006. Epub 2018 Sep 21. Cancer Treat Rev. 2018. PMID: 30300771 Review.
18FDG PET/CT in the early assessment of non-small cell lung cancer response to immunotherapy: frequency and clinical significance of atypical evolutive patterns.
Humbert O, Cadour N, Paquet M, Schiappa R, Poudenx M, Chardin D, Borchiellini D, Benisvy D, Ouvrier MJ, Zwarthoed C, Schiazza A, Ilie M, Ghalloussi H, Koulibaly PM, Darcourt J, Otto J. Humbert O, et al. Among authors: borchiellini d. Eur J Nucl Med Mol Imaging. 2020 May;47(5):1158-1167. doi: 10.1007/s00259-019-04573-4. Epub 2019 Nov 23. Eur J Nucl Med Mol Imaging. 2020. PMID: 31760467
[We must respect the anti-SARS-CoV-2 vaccine schedule without delay in cancer patients under treatment].
Barrière J, Audigier-Valette C, Borchiellini D, Hoch B, Castelnau O, Francois E, Gastaud L, Skaf R, Berdah JF, Marie W, Lescaut W, Peyrade F, Cluzeau T, Cassuto O, Carles M. Barrière J, et al. Among authors: borchiellini d. Bull Cancer. 2021 Apr;108(4):341-342. doi: 10.1016/j.bulcan.2021.02.003. Epub 2021 Mar 5. Bull Cancer. 2021. PMID: 33741139 Free PMC article. French. No abstract available.
83 results